Music, emotion, and the brain: Watanabe previews an article in this month’s issue of JNM that for the first time uses PET to document specific brain receptor changes in response to frightening music.Page 1497
Physicians’ view of oncologic PET: Karantanis and colleagues summarize the results of a survey of referring physicians’ perspectives on PET/CT cancer imaging, including interactions with imaging specialists, confidence in appropriateness of indications, utility, and practical challenges.Page 1499
PET/CT and outcome prognosis: Lim and colleagues investigate the value of staging 18F-FDG PET/CT, beyond clinical risk factors, for predicting distant metastases and survival in patients after definitive chemoradiotherapy for oropharyngeal squamous cell carcinoma.Page 1506
Early NSCLC treatment response: van Elmpt and colleagues describe the potential for early response assessment and prediction of overall survival based on 18F-FDG uptake during radiotherapy in patients with non–small cell lung cancer.Page 1514
18F-FLT PET and early response: Kishino and colleagues compare the utility of 18F-FLT with that of 18F-FDG for PET assessment of early locoregional clinical outcomes of chemoradiotherapy for head and neck squamous cell carcinomas.Page 1521
BSGC scintigraphy in DCIS detection: Spanu and colleagues evaluate the usefulness of breast-specific γ-camera scintigraphy in identification of ductal carcinoma in situ and correlate findings with screening mammography and histologic subtype.Page 1528
New PET scanners for breast imaging: Iima and colleagues report on the diagnostic performance of 2 newly developed dedicated breast PET scanners (one O- and the other C-shaped) in patients with known or suspected breast cancer.Page 1534
PET/CT in sarcoidosis: Sobic-Saranovic and colleagues assess the utility of 18F-FDG PET/CT for detection of inflammation in granulomatous sites and management guidance in patients with chronic sarcoidosis.Page 1543
Metaanalysis of PET and tinnitus: Song and colleagues review previous studies on PET evaluation of tinnitus using a coordinate-based technique to determine most commonly activated brain areas and to compare these results with those from other imaging modalities.Page 1550
Clinical 18F-desmethoxyfallypride PET: Amtage and colleagues define a clinical scan protocol with optimal quantification accuracy and timing for PET imaging with this promising tracer for longitudinal assessment of striatal dopamine in parkinsonism.Page 1558
Dopamine release detection: Ceccarini and colleagues use simulation and human studies to determine the sensitivity and optimal timing of task administration for a single 18F-fallypride PET protocol and provide a simplified model for detecting striatal and extrastriatal reward-induced dopamine release.Page 1565
Scary music and monoamine receptors: Zhang and colleagues use 11C-N-methyl-spiperone PET in healthy adults to investigate brain monoamine receptor changes induced by frightening music.Page 1573
Fiber-based Cerenkov luminescence imaging: Liu and colleagues detail the development and testing of a prototype customized fiberscopic Cerenkov imaging system with potential for guiding minimally invasive surgery.Page 1579
Islet cell apoptosis in diabetes: Watanabe and colleagues investigate the incidence of β-cell apoptosis in streptozotocin-treated mice and nonobese diabetic mice with 99mTc-annexin A5.Page 1585
Immuno-PET for Met expression: Jagoda and colleagues describe initial studies with a radiolabeled experimental therapeutic monoclonal antibody with promise for PET assessment of hepatocyte growth factor receptor (Met) in cancers.Page 1592
PET and in vivo mGluR1 metrics: Yamasaki and colleagues use 18F-FITM, a recently introduced PET ligand, to measure the affinity and density of metabotropic glutamate receptor subtype 1 in the brain of living rats.Page 1601
18F-FMISO data and Po2: Bartlett and colleagues determine whether kinetic analysis of dynamic 18F-fluoromisonidazole PET data provides better discrimination of tumor hypoxia than methods based on a simple tissue-to-plasma ratio.Page 1608
18F-labeled glutamic acid and glutamine: Ploessl and colleagues report on preparation and comparative evaluation of 18F-labeled glutamine and glutamic acid as tumor metabolic imaging agents.Page 1616
Anti-Trop-2 pretargeting epithelial cancers: Sharkey and colleagues prepare and evaluate a new anti-Trop-2× antihapten bispecific antibody with in vitro and in vivo studies to determine whether internalization properties would interfere with pretargeting in treatment of epithelial cancers.Page 1625
SNMMI guidelines in thyroid disease therapy: Silberstein and colleagues provide updated guidelines to assist practitioners in evaluating patients for 131I therapy for benign or malignant diseases of the thyroid gland, performing safe and appropriate treatment, evaluating sequelae, and reporting results.Page 1633
ON THE COVER
PET images of a patient with hypopharyngeal cancer before radiation therapy, 3 wk after the initiation of radiation therapy, and 4 wk after the end of radiation therapy.
See Page 1524.
- © 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.